TITLE

Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India

AUTHOR(S)
Solomon, Sunil Suhas; Ganesh, Aylur K.; Mehta, Shruti H.; Yepthomi, Tokugha; Balaji, Kavitha; Anand, Santhanam; Gallant, Joel E.; Solomon, Suniti
PUB. DATE
June 2013
SOURCE
Indian Journal of Medical Research;Jun2013, Vol. 137 Issue 6, p1145
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background & objectives: Sustainability of free antiretroviral therapy (ART) roll out programmes in resource-limited settings is challenging given the need for lifelong therapy and lack of effective vaccine. This study was undertaken to compare treatment outcomes among HIV-infected patients enrolled in a graduated cost-recovery programme of ART delivery in Chennai, India. Methods: Financial status of patients accessing care at a tertiary care centre, YRGCARE, Chennai, was assessed using an economic survey; patients were distributed into tiers 1- 4 requiring them to pay 0, 50, 75 or 100 per cent of their medication costs, respectively. A total of 1754 participants (ART naïve = 244) were enrolled from February 2005-January 2008 with the following distribution: tier 1=371; tier 2=338; tier 3=693; tier 4=352. Linear regression models with generalized estimating equations were used to examine immunological response among patients across the four tiers. Results: Median age was 34; 73 per cent were male, and the majority were on nevirapine-based regimens. Median follow up was 11.1 months. The mean increase in CD4 cell count within the 1st three months of HAART was 50.3 cells/µl per month in tier 1. Compared to those in tier 1, persons in tiers 2, 3 and 4 had comparable increases (49.7, 57.0, and 50.9 cells/µl per month, respectively). Increases in subsequent periods (3-18 and >18 months) were also comparable across tiers. No differential CD4 gains across tiers were observed when the analysis was restricted to patients initiating ART under the GCR programme. Interpretation & conclusions: This ART delivery model was associated with significant CD4 gains with no observable difference by how much patients paid. Importantly, gains were comparable to those in other free rollout programmes. Additional cost-effectiveness analyses and mathematical modelling would be needed to determine whether such a delivery programme is a sustainable alternative to free ART programmes.
ACCESSION #
89236751

 

Related Articles

  • Diplopia in a Patient with HIV Infection. Dhillon, Wishwdeep S.; Shah, Tushar // New England Journal of Medicine;4/15/2010, Vol. 362 Issue 15, pe52 

    The article presents a case study of a man with human immunodeficiency virus (HIV) infection who was receiving highly active antiretroviral therapy and found to have diplopia and headache for a week.

  • Early drug therapy reduces HIV transmission, study says. Taylor, Billy // Pink Paper;5/13/2011, p1 

    The article offers information on the HIV Prevention Trials Network's controlled trial conducted across Africa, Asia and the Americas, known as HPTN 052, which shows that treating an HIV-positive person with anti-retroviral therapy can reduce the risk of sexual transmission of HIV to an...

  • Preventing Antiretroviral Treatment Interruptions among HIV/AIDS Patients in Africa. Mills, Edward J.; Nabiryo, Christine // PLoS Medicine;Jan2013, Vol. 10 Issue 1, p1 

    An introduction is presented in which the editors discuss the article on the issue concerning the study which explores the antiretroviral treatment of patients with HIV and AIDS in Africa.

  • Nevirapine.  // Reactions Weekly;10/23/2010, Issue 1324, p28 

    The article describes the case of a 40-year-old woman with HIV infection who presented with maculopapular exanthema following administration with an antiretroviral three-drug treatment plus levofloxacin, referencing a study presented at the 10th Annual Meeting of the International Society of...

  • EARLY START OF HIV DRUG TREATMENT SAVES LIVES.  // International Perspectives on Sexual & Reproductive Health;Sep2010, Vol. 36 Issue 3, p121 

    The article discusses research reported by P. Severe et al. in a 2010 issue of the "New England Journal of Medicine" on early initiation of antiretroviral therapy for HIV treatment.

  • Introduction. Murphy, Robert L. // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS95 

    Discusses the challenges faced by clinicians in choosing an effective treatment regimen for patients with HIV infections. Decrease in the success rate and sustained treatment response to second-line therapies in clinics; Need to find effective treatment options that have favorable...

  • An HIV-Positive Patient Who Avoids Treatment. Legg, Jill J.; Goldschmidt, Ronald H. // American Family Physician;6/1/1999, Vol. 59 Issue 11, p3252 

    Comments on the case of an HIV-positive patient who avoids treatment. Reason for HIV-positive patients to avoid health care; Suggestions on how physicians can help HIV-positive patients go for treatment.

  • Adherence to Directly Observed Antiretroviral Therapy among Human Immunodeficiency Virus--Infected Prison Inmates. Wohl, David A.; Stephenson, Becky L.; Golin, Carol E.; Kiziah, C. Nichole; Rosen, David; Ngo, Bich; Honghu Liu; Kaplan, Andrew H. // Clinical Infectious Diseases;6/15/2003, Vol. 36 Issue 12, p1572 

    Directly observed therapy (DOT) for human immunodeficiency virus (HIV) infection is commonly used in correctional settings; however, the efficacy of DOT for treating HIV infection has not been determined. We prospectively assessed adherence to antiretroviral therapy regimens among 31...

  • Editorial Commentary: Dialing for Doses: Enhancing Community-Based Adherence Support With Mobile Technologies. Browne, Sara H. // Clinical Infectious Diseases;May2013, Vol. 56 Issue 9, p1327 

    The author discusses the study conducted by Franke et al which focuses on the treatment adherence and retention in therapy for HIV infections in rural areas in Rwanda. She mentions the comparison on the delivery of antiretroviral therapy (ART) among regional clinics in the area. She notes the...

  • HIV Testing and Treatment Among Tuberculosis Patients -- Kenya, 2006-2009. Sitienei, J.; Kipruto, H.; Nganga, L.; Ackers, M.; Odhiambo, J.; Laserson, K.; Nakashima, A. K.; Modi, S. // MMWR: Morbidity & Mortality Weekly Report;11/26/2010, Vol. 59 Issue 46, p1514 

    The article discusses a report on HIV data from Kenya's tuberculosis (TB) surveillance system from 2006 to 2009. The Kenya Division of Leprosy, Tuberculosis and Lung Disease (DLTLD) added HIV testing and treatment to its TB surveillance program at the recommendation of the World Health...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics